• The CEPH is a Research Institute founded and lead by Nobel laureate Prof. Jean Dausset
• Develops methods for high-throughput (HT) sequencing & data integration
• Realisation that the links between genome & biological processes are non-linear :

One gene = several proteins = multiple interactions = many context-dependent functions

• Undertakes the first attempts to carry-out physiological modelling via large scale data integration.
• He invents & develops the basic tools and methods required for Integrative Biology.
• Successfull completion of two models, leading to the discovery of the UCP2 and EST1 genes and their roles in obesity and hyperglycemia.
• Realisation that since published information is:
• incomplete (to an unknown extent)
• slanted (to an unknown extent), and often
• incorrect (to an unknown extent),

Methodologies to access/generate complementary unbiased information are required.

• Invents, develops & patents 4 new differential gene-expression and genotyping technologies.
• Invents & develops the computerised data gathering, data mining, clustering and integration tools & technologies necessary for the industrial development of Integrative Biology (European “Eureka” grant: 16.2 M Euros).
• Finalizes the Bio-Graph™ analytical platform
• Develops the Tamoxifen Resistance model with Bio-Graph™
• Identifies the limitations of this analytical platform

• Dr. Iris meets M.Gea and Prof. G.Dine, founding members of Centrale-Santé Healthcare & Biotech Think Tank.
• Dr. François Iris becomes a member of Centrale-Santé’s Directorate, the Healthcare & Biotech Think Tank of the Centrale's alumni's Association.
• He starts working on the second Generation analytical platform (CADI™)
• Two new models (ras-dependent breast cancer and resitance to Tamoxifen therapy) successfully completed and independently validated in-vitro.
• He starts work on the first version of the Creutzfeld-Jakob Disease model.

• Conception of the first European private biotech company specialised in Predictive Integrative biology.
• Finalize the CADI™ analytical platform.
• Four new models completed (FGF4-driven fibroblast differentiation, hypercholesterolemia, Chronic Fatigue Syndrome, Creutzfeld Jakob disease) two of which are undergoing independent biological evaluation.